News archive for Martha Enger Lab
The brain cancer immunology and therapy group will participate at the science fair in Bergen, together with the patient organization for brain tumors, hjernesvulstforeningen.
Our new paper "Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival" has been published in British Journal of Cancer.
The research laboratory for brain cancer immunology and therapy at the Department of Biomedicine has received the secretary general of the Brain-Tumour Society Rolf Ledal to discuss current and future research projects.
This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.
110 participants from Norway, Denmark, Sweden, Finland, Netherlands, Germany, and Poland converged on Nidelven in sunny Trondheim for this year´s SNOG conference on brain tumours.
Aminur Rahman, PhD, has been awarded the American Association for Cancer Research (AACR) Scholar-in-Training Award
Bortezomib as chemosensitizer for glioblastoma patients with unmethylated MGMT promoter: Phase IB/II clinical trial and mechanisms of therapeutic efficacy